Therapeutic Antibodies Market in China 2023

Therapeutic antibodies are a type of medication that is designed to target specific proteins in the body that are involved in disease processes. They are typically made from human or animal cells that have been genetically engineered to produce antibodies that can recognize and bind to a specific target protein. Once bound to the target protein, therapeutic antibodies can either block its activity or trigger an immune response against it, depending on the specific mechanism of action. Therapeutic antibodies have been developed to treat a wide range of diseases, including cancer, autoimmune disorders, infectious diseases, and inflammatory conditions. They are often used in combination with other medications, such as chemotherapy or immunosuppressive drugs, to improve treatment outcomes and reduce side effects. The therapeutic antibodies market in China is likely to register a CAGR of over 26.95% with an incremental growth of USD 42.7 billion during the forecast period 2023-2029.

This industry report offers market estimates of the China market, followed by a detailed analysis of the type. The China market data on therapeutic antibodies can be segmented by type: antibody-drug conjugate (ADC), BsAb, monospecific Ab, others.

The China therapeutic antibodies market is highly competitive. As of 2022, the major players in the China therapeutic antibodies market were 3SBio Inc., Bristol-Myers Squibb Company, Chengdu Kanghong Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Merck & Co., Novartis International AG, Roche Holding AG, Sinopharm Corporation Ltd.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
Get a detailed picture of the China Therapeutic Antibodies Market
Identify segments/areas to invest in over the forecast period in the China Therapeutic Antibodies Market
Understand the competitive environment, the markets leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Part 1. Summary
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Therapeutic antibodies market overview
Part 4. Market breakdown by type
Antibody-drug conjugate (ADC)
BsAb
Monospecific Ab
Others
Part 5. Key companies
3SBio Inc.
Bristol-Myers Squibb Company
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co.
Novartis International AG
Roche Holding AG
Sinopharm Corporation Ltd.
Part 6. Methodology

COVID-19 Outbreak-Global Female Hypoactive Sexual Desire Disorder Therapeutics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/or interpersonal difficulty.The Female Hypoactive Sexual

USD 3660 View Report

COVID-19 Outbreak-Global Pain Therapeutics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

Pain therapeutics are used to relieve pain either by stopping the pain signals or by altering the brain interpretation to these signals. Pain therapeutics have the ability to reduce pain

USD 3660 View Report

Global Arthritis Monoclonal Antibodies Market Research Report 2021-2025

Monoclonal antibodies are laboratory-produced substances that can locate and bind to specific molecules, such as tumor necrosis factor (TNF), a protein involved in causing the inflammation and damage of rheumatoid

USD 2850 View Report

Global Research Antibodies Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and Countries

The Global market for Research Antibodies is estimated to grow at a CAGR of roughly X.X% in the next 8 years, and will reach USD X.X million in 2027, from

USD 2960 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available